Essentials
• The underlying pathophysiological mechanisms behind cancer-associated thrombosis are unknown.
• We compared expression profiles in tumor cells from patients with and without thrombosis.
• Tumors from patients with thrombosis showed significant differential gene expression profiles.
• Patients with thrombosis had a proinflammatory status and increased fibrin levels in the tumor.
Summary. Background: Venous thromboembolism (VTE) is a frequent complication in patients with cancer, and is associated with significant morbidity and mortality. However, the mechanisms behind cancer-associated thrombosis are still incompletely understood. Objectives: To identify novel genes that are associated with VTE in patients with colorectal cancer (CRC). Methods: Twelve CRC patients with VTE were age-matched and sex-matched to 12 CRC patients without VTE. Tumor cells were isolated from surgical samples with laser capture microdissection approaches, and mRNA profiles were measured with nextgeneration RNA sequencing. Results: This approach led to the identification of new genes and pathways that might contribute to VTE in CRC patients. Application of INGE-NUITY PATHWAY ANALYSIS indicated significant links with inflammation, the methionine degradation pathway, and increased platelet function, which are all key processes in thrombus formation. Tumor samples of patients with VTE had a proinflammatory status and contained higher levels of fibrin and fibrin degradation products than samples of those without VTE. Conclusion: This case-control study provides a proof-of-principle that tumor gene expression can discriminate between cancer patients with low and high risks of VTE. These findings may help to further unravel the pathogenesis of cancer-related VTE. The identified genes could potentially be used as candidate biomarkers to select high-risk CRC patients for thromboprophylaxis.
Introduction
Venous thromboembolism (VTE) is a frequent complication in patients with cancer, and is associated with substantial morbidity and mortality. Cancer patients have a seven-fold higher risk of VTE than those without cancer. It has been estimated that 20% of all VTE events are related to cancer [1, 2] . Although the relationship between cancer and thrombosis is well established, the underlying pathophysiological mechanisms are still incompletely understood. Many clinical and patient-related factors are known to contribute to the VTE risk in cancer patients, such as high age, genetic disposition, immobility, and prior history of VTE [3, 4] . However, the VTE risk in these patients appears to be mainly driven by cancerrelated factors, such as high tumor grade, advanced disease stage, antineoplastic therapies, and tumor type. Tumor types are often classified into high (pancreas and brain), moderate (colon and lung) and low (breast and prostate) VTE risk groups [5] . Furthermore, cancer treatment affects the VTE risk after surgery and chemotherapy by two-fold and six-fold, respectively [3, 6] . Biomarkers hold promise for risk stratification. Knowledge about the pathophysiological mechanism underlying the prothrombotic state in cancer patients could enable the identification of new candidate biomarkers. For example, high procoagulant activity of circulating tumor cells and tumor-derived extracellular vesicles (EVs) that expose tissue factor (TF) -the primary initiator of blood coagulation -has been associated with VTE, although this finding has been questioned by others [7, 8] . Other coagulation factors, such as factor VII, which is the protease that binds TF to start coagulation, can also be upregulated in tumors [8] , potentially contributing to the development of cancer-associated thrombosis (CAT). Finally, neutrophil extracellular traps (NETs) have also been proposed to contribute to CAT [9] , although such a role for NETs in cancer patients has not yet been firmly established. Taken together, these findings indicate that the biological factors that contribute to CAT remain largely unidentified.
On average, cancer patients with VTE have a five-fold higher risk of death than those without VTE [4] . After cancer itself, thrombosis is the second cause of death in these patients [10] . Despite the high VTE risk in cancer patients, routine thromboprophylaxis in outpatients is not recommended, as it increases the risk of (fatal) major bleeding, leading to an unfavorable risk/benefit ratio when applied in all ambulant cancer patients. Selection of high-risk patients may guide decisions about thromboprophylaxis, but current prediction scores appear to perform poorly and are therefore infrequently used. Hence, it is essential to be able to predict which patients will develop VTE and who will benefit from prophylactic anticoagulants.
The aim of this study was to identify tumor-expressed genes that are associated with VTE in cancer patients and may be used as novel biomarkers for CAT. This study focused on colorectal cancer (CRC), because the prevalence of CRC is high, and it is associated with a moderate to high VTE risk. We isolated mRNA of tumor cells with lasercapture microdissection (LCM), after which a gene expression profile was determined via next-generation RNA sequencing. This enabled us to study gene expression exclusively in tumor cells, and not in the stromal compartment. Finally, we identified biological processes associated with CAT by using ingenuity pathway analysis.
Methods

Patient cohort
From a cohort of unselected patients who underwent curative or palliative surgery for CRC at the Slotervaartziekenhuis (Amsterdam, the Netherlands) between January 2008 and August 2013, a total of 206 patients were identified, of whom 19 (9.2%) were diagnosed with objectively confirmed VTE. As we defined CAT as VTE occurring within 1 year before or after CRC diagnosis, and on the basis of the availability of snap-frozen colorectal tumor specimens, we excluded seven patients. A case-control study was performed on the remaining 12 patients with confirmed VTE and patients without VTE who were individually matched on sex, age, and tumor type. Additionally, subgroup analyses were performed based on the timing of diagnosis of VTE; VTE prior to CRC diagnosis (defined as VTE at a maximum of 12 months before cancer diagnosis; four patient pairs) and VTE around the time of CRC diagnosis (defined as VTE at a maximum of 3 months before or 3 months after cancer diagnosis; five patient pairs) (Fig. 1) . Note that, because of these criteria, patient pair 1 was included in both groups. Also, on the basis of these criteria, patient pairs 9-12 were excluded from these subgroup analyses. Furthermore, in this cohort, patients with a first VTE that occurred at least 5 years before the second (cancerassociated) VTE were included.
RNA sequencing
Tumor cells were isolated from tumor specimens on the basis of morphological differences between tumor cells and stromal cells, with the LCM method. Briefly, 7-lm sections were mounted on Membrane Slide NF 1.0 PEN glasses, rehydrated, hematoxylin-treated to stain nuclei, washed in 1% ammonia, and finally dehydraded. Sections were processed on the PALM MicroBeam (Zeiss, Oberkochen, Germany) with a UV laser, and tumor cells were collected into adhesive clear cap tubes (Zeiss). To prevent RNA degradation, tumor slices were subjected to LCM within 60 min after thawing, because our pilot experiments showed that RNA is stable within a 60-min time frame, and isolated tissue was snap-frozen. LCM tissue from each patient was pooled, and RNA was isolated with the NucleoSpin RNA XS kit (Magery-Nagel, D€ uren, Germany) according to the manufacturer's instructions.
A fragment analyzer was used to assess the quality of the mRNA samples before RNA sequencing was started. The NEBNext Ultra Directional RNA library Prep Kit for Illumina was used to process the isolated RNA, after which clustering and RNA sequencing with the Illumina and NextSeq 2500 was performed according to the manufacturer's protocols at GenomeScan B.V. (Leiden, the Netherlands).
Analysis of RNA sequencing data
All RNA sequence files were processed with the BIO-PET GENTRAP PIPELINE version 0.5 developed at the LUMC (http://biopet-docs.readthedocs.io/en/latest/release notes/release_notes_0.5.0/). The BIOPET GENTRAP PIPE-LINE consists of FASTQ preprocessing (including quality control, quality trimming, and adapter clipping), read alignment, read and base quantification, and, optionally, transcript assembly. FASTQC version 0.11.2 was used for raw read quality control. Low-quality read trimming was performed with SICKLE version 1.33 with default settings. CUTADAPT version 1.9.1 with default settings was used for adapter clipping, based on the adapter sequences detected by the FASTQC toolkit. The reads were aligned against the human reference genome GRCh38 by the use of the RNA-sequencing aligner GSNAP version 2014-12-23 with settings '-npaths 1 -quiet-if-excessive'. GENCODE genome annotation version 20 was used for raw read counting. This gene read quantification step was performed with HTSEQ-COUNT version 0.6.1p1 with settings of '-stranded=no'. After TMM normalization, the differential gene expression analysis was performed with EDGER 3.14.0, by use of a model with the VTE effect and effects of matched patient-control pairs (http://bioconductor.org/packages/release/bioc/html/edge R.html) [11] . INGENUITY PATHWAY ANALYSIS (IPA) core analysis (Ingenuity Systems, Qiagen, Venlo, the Netherlands) was performed on the top 10 genes to identify the most significant pathways and (upstream) regulators.
Quantitative real-time PCR
Selected upregulated or downregulated gene expression levels were validated with real-time PCR. In brief, RNA from snap-frozen tissues was isolated with Machery-Nagel kits. Reverse transcription was performed with Superscript II (Thermo Fisher Scientific, Waltham, MA, USA), and gene expression was performed with SYBR Select (Life Technologies, Waltham, MA, USA) on a CFX284 Touch real-time PCR detection system (BioRad, Veenendaal, the Netherlands). See Table S2 for primer sequences.
Western blotting
For detection of fibrin deposition in tumors, samples were processed as described previously [12] . Briefly, equal concentrations of protein lysates were loaded onto 4-12% Bis-Tris Plus Gels (Thermo Fisher Scientific) and separated for 18 min at 200 V, and then blotted onto 0.2-lmpore poly(vinylidene difluoride) membranes and blocked for 1 h in 5% milk in Tris-buffered saline containing Tween-20 (TBST). Fibrin was detected with mAb 59D8 (a kind gift from C. Esmon, Oklahoma City, OK, USA), and the primary antibody was incubated overnight at 4°C. After multiple TBST washing steps, membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (Abcam, Cambridge, UK) for 1 h at room temperature. Antigens were visualized with Western lightning Plus ECL (Perkin-Elmer), by use of the ChemiDoc imaging system (BioRad, Oss, the Netherlands).
Results
The mean age of the selected cohort with 12 patient pairs was 71 years, and 66% of the patients were male ( Table 1 ). The distribution of deep vein thrombosis and pulmonary embolism was similar within this case-control study. No clear differences were observed in presurgerymeasured hemoglobin levels, leukocyte counts or platelet counts between patients with VTE and their control patients.
Next-generation RNA-sequencing analysis of tumor cells showed no significant differential gene expression in tumors of the selected 12 patients with VTE as compared with CRC patients without VTE (data not shown). However, when the group was separated according to the timing of the VTE in relation to the cancer diagnosis, i.e. VTE before and VTE around the time of CRC diagnosis (maximum AE 3 months), different gene profiles were observed. Analysis of the first group revealed 20 genes that were significantly upregulated or downregulated in cancer cells from patients with VTE as compared with their controls (Table S1 , left panel). After correction for multiple testing, four genes remained significantly differently expressed. Differential gene expression analysis of patients with VTE around the time of CRC diagnosis (AE 3 months) showed a panel of 30 significantly differently expressed genes, which remained after adjustment for multiple testing ( Table 2, right panel; Table S1 ).
Differentially expressed genes within these two selected patient groups are associated with a broad and diffuse set of biological pathways. Therefore, to narrow down relevant pathways and upstream regulators, we selected the top 10 differently expressed genes and performed core analysis with IPA software. IPA is a web-based set of algorithms that predict upstream and downstream cellular processes, diseases and signaling pathways associated with the observed gene expression profile. The predictions are based on comparisons with previously performed gene expression analyses. A summary of the results is shown in Table 3 . Multiple top canonical pathways and upstream regulators were identified, such as the coagulation pathway, methionine degradation and inflammation pathways via the liver X receptor (LXR) and retinoid X receptor (RXR) pathway, and interferons.
Significant upregulation of the genes SPINK4, SER-PINA1 and REG4 in samples derived from patients with VTE before CRC diagnosis was confirmed with quantitative PCR, except for patient pair 4 ( Fig. 2A-C ). SPINK4 and SERPINA1 (Fig. 2A,B) were also upregulated in at least 60% of the patients with a VTE around the time of CRC diagnosis. REG4 transcript levels were also increased in the 'VTE around the time of diagnosis' patient pairs (Fig. 2C) , except for patient pair 6. XKR9, a gene identified in the 'VTE around the time of CRC diagnosis' group, was indeed upregulated by at least threefold in patient pairs 1, 6, and 7 (Fig. 2D) , whereas downregulated expression was found in patients with VTE prior to CRC diagnosis. Both SORBS1 and NES were downregulated by at least two-fold in all patient pairs (Fig. 2E,F) . Additionally, expression of the tissue factor gene (F3) was increased in most patients who developed VTE before cancer diagnosis (Fig. 3A) ; however, whether F3 was also upregulated in patients with VTE around the time of CRC diagnosis remained inconclusive.
As inflammation was one of the top canonical pathways identified by IPA, we wished to determine whether a proinflammatory status was present in these tumor specimens. Therefore, we investigated the levels of CCL2, a key chemokine that regulates the migration and infiltration of monocytes [13] . Increased CCL2 mRNA levels were observed in most patients with VTE as compared with their controls, except for patient pairs 3 and 7 (Fig. 3B) .
Furthermore, we hypothesized that tumors from patients with VTE would have more fibrin deposition, owing to the hypercoagulant state. Therefore, fibrin levels in tumor specimens were studied with an antibody that recognizes the N-terminus of the b-chain of fibrin [12] . All tumors from patients with VTE had higher fibrin antigen levels than those from their individual control patients, except for patient pair 6 (Fig. 4) . This antibody also recognized fibrin degradation products in tumors from patients 3, 5 and 8 with VTE.
Discussion
In this study, genes were identified that are associated with the development of VTE in CRC patients. RNAsequencing results were validated with quantitative PCR on RNA isolated from whole tumors. IPA analysis was performed on the top 10 genes of the RNA-sequencing analysis, and showed that multiple pathways are affected in tumor cells from patients with VTE as compared with controls, confirming a complex relationship. An increased proinflammatory state was shown in tumors from patients with VTE. Additionally, the levels of fibrin and fibrin degradation products were increased, which suggests that a procoagulant phenotype was present in tumors of patients with VTE. Overall, these findings indicate different expression profiles in cancer cells from patients diagnosed with VTE and in cancer cells from those without VTE.
Multiple genes associated with inflammation were significantly upregulated and downregulated both in patients with VTE before CRC diagnosis and in patients with VTE around the time of CRC diagnosis ( Table 2) . It is of note that REG4 and SPINK4 are tightly regulated in inflammatory bowel disease (IBD), so coexpression of these two genes in cancer may indicate a proinflammatory status of the tumors. However, none of the patients in our cohort had a history of (known) IBD. Eventually, one in five IBD patients develop colitis-associated cancer over time [14] . Apart from the association of REG4 with inflammation, overexpression in CRC has been linked to increased tumor progression [15, 16] , suggesting that REG4 might affect both cancer and VTE.
CCL2 is a strong chemoattractant for inflammatory monocytes, which are involved in the early onset of thrombus formation [13, 17] . Indeed, an elevated CCL2 mRNA transcript level (Fig. 3B) was detected in tumor specimens from cancer patients with thrombosis.
Our study also implicates involvement of the LXR/ RXR and farnesoid X receptor (FXR)/RXR pathway. Some studies have suggested that ligands of RXR negatively regulate VTE, as increased antithrombin production and decreased platelet activation and aggregation were observed in vitro and in vivo [18, 19] . However, it must be mentioned that there are two types of platelet population during thrombosis formation: (i) activated and aggregated platelets that support thrombus growth; and (ii) loosely bound phosphatidylserine (PS)-exposing platelets with procoagulant properties [20] . It is of note that ligands of LXR and FXR, such as cholesterol derivatives, positively affect the coagulant state of platelets by increased PS exposure, EV shedding, and volume [21] . Membrane-incorporated cholesterol positively regulates TF coagulant activity and hypercoagulability [22] [23] [24] . These considerations make it likely that activation of the LXR/RXR pathway and/or the FXR/RXR pathway contribute to thrombosis in CRC patients. A hypercoagulant state could be further induced by apoptosis of tumor cells and increased XKR9 expression, leading to increased EV shedding and PS exposure [25] . One other pathway identified by IPA was methionine degradation into homocysteine. Altered methionine metabolism in tumor cells could result in increased shedding of homocysteine into the tumor milieu and/or plasma, which could result in systemic increased homocysteine levels. Multiple (epidemiological) studies have shown that increased homocysteine levels in plasma are mildly associated with VTE [26] [27] [28] . Homocysteine could increase the risk of thrombosis by influencing TF and FV function via inhibition of activated protein C (reviewed in [27] ). However, in mouse models showing increased homocysteine levels, no prothrombotic phenotype was observed [29] . This suggests that dysfunction of methionine metabolism might be a contributor to VTE, and that elevated homocysteine plasma levels, as a consequence, could serve as a potential biomarker for patients at risk.
One remarkable finding was that tumors from CRC patients with a VTE diagnosis before cancer showed a different gene profile from those with a VTE diagnosis around the time of cancer diagnosis. Two possible explanations for these disparate results can be suggested. First, patients with a VTE diagnosis around the time of cancer diagnosis have undergone cancer treatment. Surgery increases the risk of VTE by two-fold, and chemotherapy increases it by six-fold; thus, in these patients, chemotherapy and/or surgery could have contributed to the VTE risk, so this group may be biologically different from the group with a VTE diagnosis before cancer diagnosis. Second, during analysis of RNAsequencing data, not all RNA reads could be aligned to the human RNA library. This might have resulted in an underestimation of significantly differentially expressed genes in patients with VTE as compared with controls. Indeed, quantitative PCR analysis (Fig. 2) demonstrated that selected genes that were identified with our RNAsequencing approach were similarly upregulated or downregulated in both groups. Our study has a number of other limitations. We realize that the number of patients analyzed in our study was relatively small. Nevertheless, we were able to show significant expression profiles in tumors from patients with VTE as compared with non-VTE controls, providing a proof-of-concept that certain tumor-expressed genes are associated with and may even dictate a prothrombotic state in cancer patients. Increased patient numbers would, perhaps, give more detailed insights into the pathways involved. However, in general, they may reveal similar contributors to increased VTE risk, such as inflammation, cellular metabolism, and modulators of the coagulation system. Furthermore, an external validation is needed to validate these results in another CRC cohort. Additionally, we were able to detect some variation in biological processes involved in cancer patients with VTE events at different time points, suggesting that a more proinflammatory status was present in patients with VTE before diagnosis. Patients who developed VTE around the time of CRC diagnosis might have deregulated cellular metabolism and increased apoptosis. Unfortunately, no plasma samples of patients were available, so potential plasma biomarkers could not be evaluated in this cohort. Our cohort contained five patients with a prior history of VTE. The first VTE occurred at least 5 years before the second VTE, which makes it unlikely that the first VTE was cancer-related. However, VTE is a multifactorial disease, and, even when a predisposing (genetic) factor is present, cancer is likely to be a contributing factor in causing the second VTE, especially as cancer is the largest risk factor for VTE [30] . Unfortunately, we could not experimentally address whether our results would have been different if the patients with a prior history of VTE were excluded, as this would have undermined the power of our analysis.
Although the literature suggests increased hemoglobin levels, leukocyte counts and/or platelet counts as predictive biomarkers of VTE in cancer patients [31] , associations between these parameters and VTE were rather weak or absent in our cohort, but this may be the result of the relatively small cohort size. Therefore, we postulate that differential gene expression profiles show better associations with VTE in CRC patients than blood cell counts or hemoglobin levels, even in a small cohort.
This study focused on CRC, so our results cannot be extrapolated to other types of cancer. Thus, it would be interesting to investigate whether similar or, alternatively, unique tumor genes and pathways are associated with VTE in other cancer types.
In conclusion, tumor specimens of CRC patients with VTE show a different gene profile from that of tumor specimens of patients without VTE, and also increased fibrin deposition and increased inflammation. Distinct pathways might be detected and discriminated into biological pathways affecting CAT or cancer-related treatment. The newly identified genes from patients with VTE around the time of cancer diagnosis could potentially be used as candidate biomarkers in order to predict thrombosis in CRC patients who might benefit from prophylactic anticoagulants. 
Disclosure of Conflict of Interests
S. Middeldorp reports receiving grants from GSK, Aspen, Daiichi Sankyo, and Sanquin; speaker fees and participation on advisory boards for Bayer; grants, speaker fees, and participation on advisory boards for BMS-Pfizer; speaker fees from Boehringer Ingelheim; and grants and participation on steering committee for Portola, outside the submitted work. The other authors state that they have no conflict of interest.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Table S1 . List of all differently expressed genes after RNA-sequencing analysis in tumor cells from patients with VTE before CRC diagnosis (left) and VTE around the time of CRC diagnosis (right). Table S2 . Primer sequences used for quantitative PCR.
